Interleukin-9 Polyclonal Antibody

Interleukin-9 (IL-9) is a T helper 2 (Th2) type cytokine with various roles in immune regulation and inflammatory disease.^1,2 It is expressed in effector T cells, mast cells, neutrophils, eosinophils, and innate lymphoid cells in response to activation of various transcription factors, including NF-κB and nuclear factor of activated T cells (NFAT), and functions through the IL-9 receptor to induce signaling via STAT pathways and cell type-specific immune responses.^1,2,3 IL9 expression is increased in patients with asthma, and immunization with an anti-IL-9 antibody inhibits airway hyperresponsiveness in a mouse model of the disease. Antibody-based suppression of IL-9 also inhibits eosinophilia in various mouse models. IL-9 has both tumor suppressive and tumorigenic activities, enhancing T cell-mediated antitumor responses in colon cancer and promoting cell survival and multidrug resistance in diffuse large B cell lymphoma (DLBCL).⁴ Cayman’s IL-9 Polyclonal Antibody can be used for immunohistochemistry (IHC) or Western blot (WB) applications. The predicted size of IL-9 is 15 kDa and this antibody recognizes IL-9 at an observed band size of 17 kDa from mouse samples.

WARNING This product is not for human or veterinary use.

1. Hauber, H.-P., Bergeron, C., and Hamid, Q. IL-9 in allergic inflammation. Int. Arch. Allergy Immunol. 134(1), 79-87 (2004).

2. Neurath, M.F., and Finotto, S. IL-9 signaling as key driver of chronic inflammation in mucosal immunity. Cytokine Growth Factor Rev. 29, 93-99 (2016).

3. Li, H., and Rostami, A. IL-9: Basic biology, signaling pathways in CD4⁺ T cells and implications for autoimmunity. J. Neuroimmune Pharmacol. 5(2), 198-209 (2010).

4. Wan, J., Wu, Y., Ji, X., et al. IL-9 and IL-9-producing cells in tumor immunity. Cell Commun. Signal. 18(1), 50 (2020).